ScoPo’s Powerplay – Percheron as interest remains in rare diseases
Power says.“The question becomes for investors who else is out there in that rare disease space and the one we have formal research on is Percheron Therapeutics.”PER’s lead program is ATL1102, an antisense inhibitor of the CD49d receptor, which is targeting Duchenne Muscular Dystrophy (DMD).“Within the next couple of months we expect recruitment to complete for their pivotal trial and top line results should read out later in the year,” Power says
Let’s go, page-41
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
-0.001(1.27%) |
Mkt cap ! $80.86M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.0¢ | 7.7¢ | $374.4K | 4.803M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 308385 | 7.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 818650 | 4 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |